Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Identifieur interne : 004808 ( PubMed/Corpus ); précédent : 004807; suivant : 004809Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Auteurs : R. Pahwa ; J. Marjama ; D. Mcguire ; K. Lyons ; F. Zwiebel ; P. Silverstein ; R. Ward ; W C KollerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1996.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacokinetics), Biological Availability, Carbidopa (administration & dosage), Carbidopa (pharmacokinetics), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Female, Humans, Levodopa (administration & dosage), Levodopa (pharmacokinetics), Male, Metabolic Clearance Rate (physiology), Motor Skills (drug effects), Neurologic Examination (drug effects), Parkinson Disease (blood), Parkinson Disease (drug therapy), Therapeutic Equivalency.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Carbidopa, Levodopa.
- blood : Parkinson Disease.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Parkinson Disease.
- physiology : Metabolic Clearance Rate.
- Administration, Oral, Aged, Biological Availability, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Female, Humans, Male, Therapeutic Equivalency.
Abstract
We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single-dose double-blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, or walking time. In this single-dose study, there were no significant differences in pharmacokinetic and motor responses between Sinemet and Atamet.
DOI: 10.1002/mds.870110412
PubMed: 8813223
Links to Exploration step
pubmed:8813223Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R" last="Pahwa">R. Pahwa</name><affiliation><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J" last="Marjama">J. Marjama</name></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D" last="Mcguire">D. Mcguire</name></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K" last="Lyons">K. Lyons</name></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F" last="Zwiebel">F. Zwiebel</name></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P" last="Silverstein">P. Silverstein</name></author><author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R" last="Ward">R. Ward</name></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W C" last="Koller">W C Koller</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8813223</idno><idno type="pmid">8813223</idno><idno type="doi">10.1002/mds.870110412</idno><idno type="wicri:Area/PubMed/Corpus">004808</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R" last="Pahwa">R. Pahwa</name><affiliation><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J" last="Marjama">J. Marjama</name></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D" last="Mcguire">D. Mcguire</name></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K" last="Lyons">K. Lyons</name></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F" last="Zwiebel">F. Zwiebel</name></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P" last="Silverstein">P. Silverstein</name></author><author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R" last="Ward">R. Ward</name></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W C" last="Koller">W C Koller</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Biological Availability</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (pharmacokinetics)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacokinetics)</term><term>Male</term><term>Metabolic Clearance Rate (physiology)</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Therapeutic Equivalency</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Metabolic Clearance Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Biological Availability</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Therapeutic Equivalency</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single-dose double-blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, or walking time. In this single-dose study, there were no significant differences in pharmacokinetic and motor responses between Sinemet and Atamet.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8813223</PMID><DateCreated><Year>1996</Year><Month>12</Month><Day>26</Day></DateCreated><DateCompleted><Year>1996</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>1996</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.</ArticleTitle><Pagination><MedlinePgn>427-30</MedlinePgn></Pagination><Abstract><AbstractText>We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single-dose double-blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, or walking time. In this single-dose study, there were no significant differences in pharmacokinetic and motor responses between Sinemet and Atamet.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marjama</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zwiebel</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Silverstein</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>W C</ForeName><Initials>WC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008657">Metabolic Clearance Rate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013810">Therapeutic Equivalency</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8813223</ArticleId><ArticleId IdType="doi">10.1002/mds.870110412</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004808 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004808 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8813223
|texte= Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8813223" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |